13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      822
      Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects

      abstract

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background.  Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (GT 1-6) activity in vitro. Asunaprevir (ASV) is a selective NS3 protease inhibitor with in vitro activity against GT 1, 4, 5 and 6. These two direct-acting antivirals (DAA) are in phase 3 development and regulatory review as a dual-DAA regimen (DCV + ASV) for the treatment of HCV GT 1b. DCV and ASV both inhibit P-glycoprotein (P-gp) and individually increase plasma concentrations of the P-gp substrate digoxin (DIG), increasing DIG Cmax by 65 and 9% and AUCTAU by 27 and 30%, respectively. The combined effect of DCV + ASV on the pharmacokinetics (PK) of DIG was therefore assessed in healthy subjects. Methods.  A single sequence, open-label, one-way interaction study assessed the effect of steady-state DCV (60 mg QD) plus ASV (100 mg BID [softgel capsule]) on the PK of single-dose 0.25 mg DIG in healthy subjects. Subjects (N = 16) received DIG on Day 1 and 16, and DCV + ASV on Days 6–20. Serial samples for DIG plasma concentrations were collected up to 120 h postdose on Day 1 and Day 16. Non-compartmental DIG PK parameters were derived. Geometric mean ratios (GMR) and 90% confidence intervals (90%CI) for DIG Cmax and AUCinf were derived from linear mixed effects models. Results.  All subjects (69% male, aged 23-45 years) completed the study. DCV + ASV dosed with DIG resulted in a 77% increase in DIG Cmax and a 29% increase in AUCinf (Table). Study drugs were well tolerated; all AEs were mild in intensity except 2 AEs of increased blood creatinine phosphokinase (1 moderate, 1 severe). No AEs were considered study drug-related and all resolved by study end. With DCV+ASV Adj. Geo. Mean (90%CI) W/O DCV+ASV Adj. Geo. Mean (90%CI) GMR (90%CI) DIG Cmax , pg/mL 1593 (1407, 1803) 902 (797,1021) 1.766 (1.504, 2.073) DIG AUCinf , pg×h/mL 23293 (21522, 25209) 18090 (15818, 20689) 1.288 (1.197, 1.385) Conclusion.  DCV and ASV effects on DIG PK are not additive and are similar to DCV alone. Caution is warranted when dosing DCV + ASV with DIG and other P-gp substrates with a narrow therapeutic window; a priori dose modification does not appear to be required. Therapeutic drug monitoring, if available, may be considered. Disclosures.   T. Garimella, Bristol-Myers Squibb: Employee, Salary R. Adamczyk, Bristol-Myers Squibb: Employee and Shareholder, Salary M. Stonier, Bristol-Myers Squibb: Employee, Salary H. Kandoussi, Bristol-Myers Squibb: Employee, Salary M. Hesney, Bristol-Myers Squibb: Employee, Salary E. Colston, Bristol-Myers Squibb: Employee, Salary T. Eley, Bristol-Myers Squibb: Employee and Shareholder, Salary M. Bifano, Bristol-Myers Squibb: Employee, Salary

          Related collections

          Author and article information

          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          ofids
          Open Forum Infectious Diseases
          Oxford University Press
          2328-8957
          December 2014
          December 2014
          : 1
          : Suppl 1 , IDWeek 2014 Abstracts
          : S235
          Affiliations
          [1 ]Research and Development, Bristol-Myers Squibb, Hopewell, NJ
          [2 ]Bristol-Myers Squibb Research and Development, Lawrenceville, NJ
          Author notes

          Session: 107. Clinical - Clinical Trials

          Friday, October 10, 2014: 12:30 PM

          Article
          ofu052
          10.1093/ofid/ofu052.530
          5781887
          593facbc-6064-4aba-af4a-408aa1af7e4a
          © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America
          History
          Categories
          IDWeek 2014 Abstracts
          Poster Abstracts

          Comments

          Comment on this article